Subscribe
Acute and sustained treatment with ulotaront did not show a statistically significant decrease from placebo in total number of cataplexy events and had no significant change in other symptomatic ratings over a 2-week treatment period.
NeurologyLive® Brain Games: September 17, 2023
NeurologyLive® Friday 5 — September 15, 2023
Opioids Improve Disturbed Nocturnal Sleep and Excessive Daytime Sleepiness in Narcolepsy Type 1
Longer Sleep Latency Time Observed With Recent Definition of Sleep Onset, Meta-Analysis Shows
Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD
Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA
Basil T. Darras, MD
Karissa Gable, MD
Anne M. Connolly, MD, FAAN; Amy Moore, PhD
James F. Howard Jr, MD, FAAN
Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP